NBIX - Neurocrine Biosciences PEG Multiple

Symbol and logo of brand Neurocrine Biosciences (NBIX)

The PEG ratio demonstrates the resilience of Neurocrine Biosciences (NBIX), as the indicator stands at 0.45. Stable demand for neurological drugs makes this defensive asset insensitive to market cycles. The company achieves cost optimization by utilizing external contract manufacturing organizations. R&D efficiency is enhanced through the implementation of robotic bio-screening systems, which significantly accelerates the development of new drugs.

NBIX: Neurocrine Biosciences Price/Earnings to Growth Ratio 07/04/2022 - 11/17/2026

Metric breakdowns and analytics for Neurocrine Biosciences, Inc. (NBIX)

- current quotes and average value forecast:
General company analysis:NBIX, Neurocrine Corp
Original product of neurocrine.com

For Neurocrine Biosciences (NBIX), which competes in the high-risk neurology sector, the growth stock undervaluation ratio visualizes the balance between market price and the pace of earnings expansion. The metric is calculated by dividing the P/E by the expected EPS growth percentage; a value below one signals a fundamental discount, which is critical when assessing the potential of the company's monopoly patent rights.

Competitors of Neurocrine Biosciences

Growth-Adjusted Market Cap to Net Income Biogen Idec|PEG Multiple RGC (Regencell Bioscience Ltd)|Growth-Adjusted Market Cap to Net Income axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Price/Earnings to Growth Ratio|Supernus Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple CPRX|Denali Therapeutics Inc. (DNLI) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple HRMY (Harmony Corp)|BHVN - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Amylyx Pharmaceuticals, Inc. AMLX|Growth-Adjusted Payback Ratio TRVI|PRAX - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Anavex Life Sciences AVXL|CBLL: PEG Multiple|Price/Earnings to Growth Multiple Prothena Corporation PLC|ALEC (alector.com) - PEG Multiple|Price/Earnings to Growth Multiple Annexon, Inc. (ANNX)|Price/Earnings to Growth Ratio Omeros Corporation (OMER)|Neurogene Inc. - Growth-Adjusted P/E Ratio|acimmune.com - Price/Earnings to Growth Multiple|PEG Multiple Voyager Therapeutics Inc VYGR|NMRA - Price/Earnings to Growth Ratio|Price to Net Income Growth Ratio Scilex Holding Company (SCLX)|Tevogen Bio Holdings (TVGN) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ACOG|Price/Earnings to Growth Ratio Cognition Therapeutics, Inc.|Inhibikase Therapeutics, Inc. - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple SAVA (Cassava)|Growth-Adjusted Market Cap to Net Income Assertio Therapeutics|Coya Therapeutics, Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio VTGN (VistaGen Therapeutics Inc)|Ovid Therapeutics Inc - PEG Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Multiple|CRVO (CervoMed, Inc.) - Price/Earnings to Growth Multiple|Price/Earnings to Growth Multiple Alterity Therapeutics Ltd|Price/Earnings to Growth Ratio Clene Inc.|PepGen Inc. - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple JUNS (Jupiter Neurosciences Inc)|Price/Earnings to Growth Ratio RLMD (Relmada Therapeutics Inc)|Annovis Bio Inc - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Grace Tx (GRCE)|fireflyneuro.com - PEG Multiple|Klotho Neurosciences (KLTO) - Price/Earnings to Growth Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio RVPH (Reviva Pharmaceuticals Holdings, Inc.)|MTVA (MetaVia) - PEG Multiple|NRXS: Growth-Adjusted Payback Ratio|PEG Multiple HSDT|PEG Multiple Passage Bio Inc. (PASG)|Price/Earnings to Growth Ratio bionomics.com.au NEUP|PEG Multiple Minerva Neurosciences Inc NERV|ATHA: Price/Earnings to Growth Multiple|ADXN (Addex Therapeutics, Ltd.) - Growth-Adjusted P/E Ratio|Alzamend Neuro Inc. (ALZN) - Price/Earnings to Growth Ratio|Cyclerion - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio protagenic.com|Pasithea Therapeutics - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Brainstorm Cell BCLI|PEG Multiple caratherapeutics.com CARA|Chromocell Therapeutics Corp. - PEG Multiple|eliemtx.com - Company Value to Earnings Growth Ratio|Intra-Cellular Therapies (ITCI) - Price/Earnings to Growth Ratio|LBPH (Longboard) - Price/Earnings to Growth Ratio|MRNS (marinuspharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NKGen Biotech NKGN|Price/Earnings to Growth Ratio NeuroBo Pharma (NRBO)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix, Inc. - Price/Earnings to Growth Multiple|TRVN: Growth-Adjusted P/E Ratio|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical, Inc.)|CERE: PEG Multiple